Overview Markets Watchlist

© 2026 IR SuperintelMethodology Contact

Nabriva Therapeutics PLC

CUSIP: G63637903 | 3 institutional holders

Quarters

Q2 2022 Q1 2022 Q4 2021 Q3 2021 Q2 2021

Compare Detailed Historical Funds Options Short Interest 13D/13G Peers Targeting Trading Summary Profile